|
Bookmark this page: www.oecd.org/health/pharmaceutical.
Aims
The OECD Pharmaceutical Pricing Policy project has two main objectives:
-
To add to the base of information about pharmaceutical pricing policy in OECD countries and develop a taxonomy and framework for making international comparisons of policies.
-
To analyze cross-national impacts and implications of policies, particularly with respect to the impacts on pharmaceutical prices paid in other countries and on pharmaceutical R&D.
The approach for implementing this study involves two streams of work. The first will develop the information base for analytical work, accomplished primarily through the development of a framework to support cross-national comparisons of pharmaceutical pricing policies, the review and synthesis of existing information and the enhancement of the information base via original data collection. An important output from this phase of the project is the publication of country-specific reports that describe and analyse the policy impacts of pharmaceutical policies in each case-study subject country.
The main focus of the second work stream will be to assess the prospective cross-national or global policy impact of pricing and reimbursement policies.
Key outputs will be a taxonomy of pricing and reimbursement policies and analyses focusing on a set of issues that are important to assessing the cross-national impact of these policies.
Topics to be addressed include:
-
The interaction of pricing and reimbursement policies with the drivers of pharmaceutical R&D, and their impact on global pharmaceutical R&D and the innovation process;
-
The impact of pricing and reimbursement policies on pharmaceutical prices and the availability of drugs in other OECD countries, including the extent to which there has been harmonisation of market-entry price levels for innovative drugs;
-
How manufacturers behave in response to government policies and regulations.
In addition, the impacts within a country of different pricing and reimbursement policies will be examined, drawing upon the assessments from the case study reports.
Project administration and consultation
The work is being undertaken by the Health Division in the Directorate for Employment, Labour and Social Affairs. Given that the issues to be addressed cut across a number of disciplines and portfolios within governments, the work is being done in close consultation with other Directorates, notably the Directorate for Science, Technology and Industry (particularly the Biotechnology Division).
Co-ordination with relevant work undertaken elsewhere in the Organisation and by other international organisations is viewed by the Secretariat as critical to this project’s success. In particular, the Secretariat has continued its close co-operation with the European Commission’s Pharmaceutical Pricing and Reimbursement Information project.
Contact:
Ms. Elizabeth Docteur: elizabeth.docteur@oecd.org
Ms. Valérie Paris: valerie.paris@oecd.org
Mr. Pierre Moïse: pierre.moise@oecd.org
Project Timeline
December 1-2, 2005. A technical meeting of national and invited experts was held. The agenda included invited presentations on relevant work in progress or recently completed to explore potential synergies and hone in on the issues that remain to be addressed. A draft framework and taxonomy for assessing pharmaceutical pricing policies was also discussed.
Spring 2006. Case studies of pharmaceutical pricing policy in Canada and Mexico were undertaken.
Summer-autumn 2006. Case studies of pharmaceutical pricing policy in Switzerland, Sweden and Germany were undertaken.
November 27 2006. A second technical meeting of national and invited experts was held. As with the first technical meeting, presentations on relevant work from other projects were provided. Preliminary analysis from the 5 case studies conducted to date was presented. Experts were invited to comment and discuss the Secretariat’s proposed methodology on how to proceed with the second work stream, providing direction on next steps.
Winter 2006-2007. Case study reports on Canada and Mexico released as Health Working Papers.
Summer 2007. Case study reports on Switzerland and Sweden were released as Health Working Papers.
September 24 2007. A third technical meeting reviewed the draft final report from the project. Experts were invited to comment on issues raised by the Secretariat and raise for discussion other important issues not brought to the attention of the Secretariat. The experts also provided feedback on preliminary conclusions presented by the Secretariat. The draft report will be revised in light of discussions at the expterts' meeting and the OECD Health Committee.
November 2007. In light of the expert group's advice, the Secretariat will present the project's draft conclusions to delegates of the 2nd meeting of the OECD Health Committee.
First Quarter 2008. Case study reports on Slovakia and Germany to be released as Health Working Papers.
June 2008. The final report from the project is expected to be published.
Second Quarter 2008. Based on recommendations from the Health Committee, the OECD may organised a high-level meeting in Paris, or elsewhere at the invitation of a member country interested in hosting this event.
Project Output
Previous OECD studies on pharmaceuticals
|
The most comprehensive source of comparable statistics on health and health systems across OECD countries
This 4th edition of Health at a Glance provides the latest comparable data on the performance of health systems in OECD countries
Focus on Health
